The Lift Line
“For decades India answered the world’'s medical needs by making old drugs cheaply. Antimicrobial resistance is asking a harder question: can it make new ones?”
On June 1, 2026, the US FDA approved Zaynich (cefepime-zidebactam), an intravenous antibiotic from the Indian firm Wockhardt, the first new chemical entity discovered and developed by an Indian company to win FDA approval. It arrived at the very moment antimicrobial resistance (AMR) is turning India’'s cheap-generics strength into an incomplete answer. This editorial argues that AMR is shifting the pharma challenge from access to innovation, and India must move up the value chain.
Why This Editorial Matters for Your Exam
GS Paper 3: Science and technology developments and their applications; indigenisation of technology and developing new technology; issues relating to intellectual property rights. It also links to GS Paper 2 through health policy, the National Action Plan on AMR and the governance of a public-health threat.
This theme lets you connect public health, the economics of innovation, self-reliance in high technology and India’'s global role in medicine into a single argument, useful for GS3 science-and-tech and GS2 health-governance answers alike.
Background and Context
Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites evolve to resist the drugs designed to kill them, rendering standard treatments ineffective.
The burden is enormous. A Lancet GRAM study (published 2022) attributed about 1.27 million deaths directly and 4.95 million associated deaths to bacterial AMR in 2019, more than HIV or malaria. A 2024 GRAM forecast projects more than 39 million cumulative directly attributable deaths between 2025 and 2050.
India is a global AMR hotspot. Per NARS-Net (National Antimicrobial Resistance Surveillance Network) data, over half of Klebsiella pneumoniae isolates are carbapenem-resistant, and colistin resistance, a last-resort concern, is rising. Drivers include over-the-counter sales, overuse in humans and livestock, weak stewardship and pharmaceutical effluent.
The Core Argument / Issue
The central claim is that AMR transforms the pharmaceutical challenge itself. India’'s greatness has been in access, making existing drugs affordable, but AMR demands new molecules, which requires discovery, not just manufacturing.
The Generics Strength and Its Ceiling
| Metric | India’'s position |
|---|---|
| Share of global generics by volume | About 20 per cent |
| Global vaccines supplied | About 60 per cent |
| Pharma industry rank by volume | Third-largest |
| Pharma industry rank by value | Only fourteenth |
| Pharma exports (FY2024-25) | About 30 billion dollars |
| Gross R&D as share of GDP | About 0.64 per cent |
India is the pharmacy of the world in volume but small in value. India’'s overall research intensity is low at about 0.64 per cent of GDP, and its drugmakers reinvest a far smaller share of revenue in research than innovator pharma, which spends about 15 to 21 per cent of revenue. A model built on making old drugs cheaply cannot, by itself, defeat pathogens that outrun those drugs.
Zaynich as a Marker
Zaynich (cefepime-zidebactam, developmental code WCK 5222) is FDA-approved for complicated urinary tract infections including pyelonephritis caused by susceptible Gram-negative bacteria. Its significance is larger than its label: it works even in the presence of many beta-lactamases, including metallo-beta-lactamases that defeat carbapenems, and in a Phase 3 trial (ENHANCE-1) showed a composite success rate of about 89 per cent versus 68 per cent for meropenem. It proves an Indian firm can discover, not just copy.
The Policy Response
India’'s National Action Plan on AMR (NAP-AMR) 2.0, launched November 18, 2025 for 2025-2029, places intersectoral oversight under NITI Aayog with a One Health approach across 20-plus ministries. It builds on the 2016 Red Line Campaign (a red vertical line marks prescription-only antibiotics) and Schedule H1 restrictions on over-the-counter antibiotic sales, both weakened by poor enforcement.
The Honest Counter
Antibiotic R&D faces a structural market failure: a good new antibiotic must be conserved, used as little as possible to preserve its power, which collapses sales volume and returns. This is why global pharma largely exited antibiotic discovery, and why one Indian success cannot alone fix the broken economics or India’'s low R&D intensity.
How to Think About This (Analytical Frame)
Separate the access problem from the innovation problem. For most diseases India’'s challenge is delivering existing drugs cheaply, a strength. For AMR, existing drugs are the problem, because resistance is outpacing the generic arsenal. Ask which problem a given policy solves. Price controls and generics serve access; pull incentives, stewardship and R&D funding serve innovation. Conflating the two produces cheap drugs that no longer work. AMR is the case where India must consciously fund the second problem.
The Diagram in Words
AMR rising -> 1.27 million direct deaths (2019), 39 million+ projected cumulative 2025-2050 -> India a hotspot (over 50% Klebsiella carbapenem-resistant) -> existing generics failing against resistant bugs -> India strong in access (20% of global generics by volume) but weak in value (14th) and R&D (0.64% of GDP) -> access model cannot beat resistance -> need new molecules -> Zaynich (cefepime-zidebactam), first Indian FDA new chemical entity, June 1 2026, works vs many resistant Gram-negatives -> but antibiotic economics broken (conserve = low sales) -> fix: NAP-AMR 2.0 + stewardship + Schedule H1 enforcement + pull incentives + higher R&D -> move from pharmacy of the world to discoverer of new drugs
Way Forward
- Implement NAP-AMR 2.0 fully. Use its NITI Aayog oversight and One Health design to enforce time-bound, budgeted accountability across ministries.
- Strengthen stewardship and Schedule H1. Curb over-the-counter antibiotic sales, enforce the Red Line, and improve diagnostics so antibiotics are used correctly.
- Fix the innovation economics. Adopt pull incentives, subscription or delinked-payment models like the UK’'s, and partner with bodies such as GARDP to fund novel antibiotics that must be conserved.
- Raise pharma R&D intensity. Support translational research, public-private discovery and value-chain movement so more new chemical entities emerge from India, not just generics.
PYQ Linkage and Practice
- UPSC GS3 (2019): “How is the Government of India protecting traditional knowledge of medicine from patenting by pharmaceutical companies?” (pharma and IP)
- UPSC GS2 (2018): “Appropriate local community-level healthcare intervention is a prerequisite to achieve ‘Health for All’ in India. Explain.”
- UPSC GS3 (2015): Questions on India’'s scientific research and the role of R&D.
Practice Mains question (250 words, 15 marks): “Antimicrobial resistance is shifting India’‘s pharmaceutical challenge from access to innovation. Discuss the limits of the low-cost generics model, the significance of India’'s first FDA-approved new molecule, and the reforms needed to make original antibiotic discovery viable.”
Sources: Business Standard, PIB, Ministry of Health and Family Welfare
Source: Looking Beyond Generics: Why AMR Is Rewriting India's Pharma Challenge — Ujiyari.com | Free UPSC & State PCS Editorial Analysis
